Table 1. Patient Characteristics.
| Median age (range) | 78 (41 - 81) |
| Age ≥ 60 years old (%) | 4/5 (80%) |
| Male (%) | 3/5 (60%) |
| No. Caucasian (%) | 5/5 (100%) |
| ECOG performance status | |
| 0 - 1 | 1/5 (20%) |
| 2 | 4/5 (80%) |
| 3 | 0 (0%) |
| Median duration of CR1 in months (range) | 3 (3 - 11) |
| Refractory disease (%) | 2/5 (40%) |
| Previous lines of salvage | |
| 0 | 0 (0%) |
| 1 | 2/5 (40%) |
| 2 | 1/5 (20%) |
| > 2 | 2/5 (40%) |
| Antecedent hematologic disorder | 1/5 (20%) |
| Previous HDAC or IDAC-based salvage | 4/5 (80%) |
| ELN 2017 cytogenetic risk score | |
| Good risk | 0/5 (0%) |
| Intermediate risk | 2/5 (40%) |
| Poor risk | 3/5 (60%) |
| Median %blasts in marrow (range) | 29% (15-49%) |
CR1: first complete remission; HDAC: high-dose cytarabine (Ara-C); IDAC: intermediate-dose Ara-C.